Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

Learn more about whether Alcon Inc. or Hologic, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

On the Surgical side, growth is expected to be led by the core MyoSure and the platform's complementary fluent fluid management system. Hologic’s international business performance may have ...

Hologic HOLX is set to release first-quarter fiscal 2025 results on Feb. 5 after the closing bell. Stay up-to-date with all ...

Hologic’s gantry business ... We expect the segment’s performance to be driven by robust sales of MyoSure devices and related Fluent fluid management products. The international Surgical ...

With Hologic, Inc. HOLX gearing up to release its fiscal 2025 first-quarter financial results on Feb. 5 after the market ...

Hologic, Inc. engages in the development ... and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the ...

Zacks Investment Research Image Source: Zacks Investment Research In the last four quarters, Hologic surpassed the consensus mark three times and missed once, the average surprise being 3.07%.

Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates ...